The GLP-1 boom has a dark side — even if serious complications are rare
Lawsuits raise a difficult question: When millions of people are taking new drugs, how much evidence of a devastating risk is enough to require a warning?
Originally published by WaPo National. Summary and curation by DutyStation News.


